Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Congestive Ophthalmopathy

rosiglitazone has been researched along with Congestive Ophthalmopathy in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Frascerra, S; Santini, E1
Antonelli, A; Bernini, G; Fallahi, P; Ferrannini, E; Ferrari, SM; Frascerra, S; Gelmini, S; Pupilli, C; Ruffilli, I; Sellari-Franceschini, S1
Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Romagnani, P; Rotondi, M; Serio, M1
Goldberg, RA; Lee, S; McCann, JD; Tsirbas, A1
Aberg, M; Asman, P; de Capretz, A; Frenander, C; Groop, L; Hallengren, B; Lantz, M; Parikh, H; Vondrichova, T1

Other Studies

5 other study(ies) available for rosiglitazone and Congestive Ophthalmopathy

ArticleYear
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:5

    Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Graves Disease; Graves Ophthalmopathy; Humans; Hypoglycemic Agents; Interferon-gamma; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thyroid Gland; Tumor Necrosis Factor-alpha

2009
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
    The Journal of endocrinology, 2012, Volume: 213, Issue:2

    Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy; Humans; Interferon-gamma; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha

2012
Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:2

    Topics: Adult; Cell Differentiation; Chemokine CXCL10; Chemokines, CXC; Female; Fibrinolytic Agents; Graves Ophthalmopathy; Humans; Interferon-gamma; Lymphocyte Activation; Male; PPAR gamma; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Tumor Necrosis Factor-alpha

2006
Thiazolidinedione induced thyroid associated orbitopathy.
    BMC ophthalmology, 2007, Apr-26, Volume: 7

    Topics: Diplopia; Disease Progression; Drug Therapy, Combination; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Metformin; Middle Aged; Propranolol; Propylthiouracil; Retreatment; Rosiglitazone; Thiazolidinediones

2007
COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy.
    Thyroid : official journal of the American Thyroid Association, 2007, Volume: 17, Issue:6

    Topics: Adipocytes; Adipogenesis; Cell Differentiation; Cyclooxygenase 2; Dexamethasone; Diclofenac; Gene Expression; Graves Ophthalmopathy; Humans; Insulin; Rosiglitazone; Stearoyl-CoA Desaturase; Thiazolidinediones

2007